New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For AAPL;JPM;RDSA;NVS;BKS;WDC;GD;VIA;VIAB;BLK;MPC From The Last 14 Days
Check below for free stories on AAPL;JPM;RDSA;NVS;BKS;WDC;GD;VIA;VIAB;BLK;MPC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>
April 22, 2014
05:35 EDTNVSNovartis says transactions 'represent a transformation' for the company
The elements of the transaction with GSK (GSK) are inter-conditional and subject to approval by GSK shareholders. The Novartis (NVS) board unanimously believes that the transactions with GSK and the transaction with Lilly (LLY) are in the best interests of Novartis and the Novartis Shareholders as a whole. The transaction with Lilly is expected to close by the end of 1Q15 and the transaction with GSK is expected to close during the first half of 2015. The terms of the divestment of the Vaccines business would maximize the value of its pipeline, including Bexsero. The divestment of Animal Health would recognize the full value of the business. The transactions are expected to improve Novartis' sales and core operating income growth rates, while improving margins. Each of the transactions is projected to be value creating. The company commented, "These transactions represent a transformation for Novartis. We have leading positions in our core businesses in high-growth segments of healthcare. This will enable us to continue to build the world's most respected and successful healthcare company. Our strategic focus on science-based innovation and our global scale position the company well to meet the changes in the healthcare industry for the coming decade and beyond."
05:29 EDTNVSNovartis divests Animal Health Division to Eli Lilly for about $5.4B
Subscribe for More Information
05:26 EDTNVSNovartis OTC, GSK Consumer Healthcare form joint venture
Subscribe for More Information
05:23 EDTNVSNovartis divests Vaccines business to GSK for $7.1B
Novartis (NVS) has agreed to divest its Vaccines business to GSK (GSK), currently excluding its flu business, for $7.1B plus royalties. The $7.1B consists of $5.25B upfront and up to $1.8B in milestones. As a part of a value-maximization strategy in the context of the portfolio review, Novartis has initiated a separate sales process for its flu business.
05:20 EDTNVSNovartis to acquire GSK oncology products for $14.5B
Subscribe for More Information
April 21, 2014
16:01 EDTAAPLOptions Update; April 21, 2014
iPath S&P 500 VIX Short-Term Futures down 78c to 40.03. Option volume leaders: AAPL C GILD NFLX TSLA TWTR FB WLT according to Track Data.
15:05 EDTAAPLApple recruiting employees for mobile payments, Re/code says
Subscribe for More Information
14:40 EDTAAPLWi-LAN files appeal in patent suit with Apple
Wi-LAN (WILN) announced that it has filed an appeal with the United States Court of Appeals for the Federal Circuit in its patent dispute with Apple (AAPL) involving WiLAN's U.S. Patent No. RE37,802. On April 3, Judge Rodney Gilstrap of the U.S. District Court for the Eastern District of Texas, ruled that the Jury had no basis for invalidating the 802 patent at the trial of the WiLAN vs. Apple lawsuit in October 2013. In addition to this case, WiLAN is in litigation with Apple in the Southern District of California concerning the infringement of two patents related to LTE technology. WiLAN expects the case in Southern California to go to trial later this year if not settled earlier.
11:34 EDTAAPLApple April weekly volatility elevated at 50 into Q2
Subscribe for More Information
10:01 EDTMPCOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:36 EDTAAPLActive equity options trading on open
Subscribe for More Information
09:32 EDTAAPLJabil Circuit downgraded at RBC Capital
As noted earlier, RBC Capital downgraded Jabil Circuit (JBL) to Sector Perform from Outperform. As reasons for the downgrade, the firm cited concerns about Jabil circuit's largest customer, Apple (AAPL), as well as its belief that Jabil's FY15 guidance appears to reflect a best-case scenario. Target to $20 from $21.
08:40 EDTMPCMarathon Petroleum downgraded to Outperform from Focus List at Howard Weil
08:18 EDTNVSMomenta Pharma rises after high court rejects Copaxone delay bid
Shares of Momenta Pharmaceuticals (MNTA) are higher in pre-market trading after the Supreme Court denied Teva's (TEVA) request to delay the launch of generic forms of its relapsing-remitting multiple sclerosis product, Copaxone. WHAT'S NEW: Teva confirmed on April 19 that the Chief Justice of the United States denied the company's application for an injunction seeking to prevent the launch of a generic version of Copaxone. Teva will continue pursuing its appeal in the Supreme Court and defending its intellectual property for Copaxone, the company said. WHAT'S NOTABLE: Momenta has developed a generic version of Copaxone in partnership with Novartis' (NVS) Sandoz unit. Mylan, which is preparing to launch a generic version of Copaxone as well, said after the ruling: "We are pleased with the Chief Justice's decision, and we look forward to introducing the first generic Copaxone treatment for multiple sclerosis patients in the U.S. at market formation. Mylan remains eligible to receive approval from the U.S. FDA on May 25, 2014." PRICE ACTION: In pre-market trading, Momenta shares are up over 12% to $12.46, while Mylan shares are up more than 3% to $48.48. Teva shares trading in New York are down about 1.7% to $50 in pre-market trading.
07:46 EDTAAPLApple to add call credit payments in China, Marbridge Daily says
Subscribe for More Information
07:21 EDTNVSFDA Pediatric Advisory Committee to hold a meeting
The Committee discusses pediatric-focused safety reviews including MDT's Activa Dystonia Therapy, (BAX's Advate and Tisseel, NVS' Famvir, Tibotec's (JNJ subsidiary) Intelence, UCB Pharma's Keppra, MRK's Maxalt, BAYRY's Natazia, Digestive Care's Pertzye, JNJ's Prezista, BMY's Reyataz, SNY's Sklice, PFE's Torisel, Aptalis' Ultresa, and GILD's Viread in a meeting being held in Bethesda, Maryland on April 21 at 8 am. Webcast Link
06:48 EDTAAPLMicrosoft faces internal & external conflicts in three segments, DigiTimes says
Subscribe for More Information
06:45 EDTAAPLApple and Google compete to offer exclusive game apps, WSJ reports
Subscribe for More Information
06:37 EDTAAPLSquare discusses possible sale as losses widen, WSJ reports
Mobile-payments startup Square discussed a possible sale to several rivals as its losses widen, reports the Wall Street Journal, citing people familiar with the matter. Google (GOOG) discussed a possible acquisition of the company earlier this year, but it was not clear if the talks were continuing. Square also had discussions about a deal with Apple (AAPL) and eBay's (EBAY) PayPal. Reference Link
06:27 EDTAAPLApple revenue outlook likely to miss expectations, says Piper Jaffray
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use